Navigation Links
Hormone replacement therapy appears to have no effect on risk and severity of rheumatoid arthritis
Date:2/27/2008

Although rheumatoid arthritis (RA) is more predominant in women, the reasons for this are unclear. Many studies have examined the effects of estrogen on the risk and severity of RA, but the results are conflicting and controversial. A new study using data from the Womens Health Initiative (WHI) clinical trials on hormone replacement therapy found that there were no significant differences in the risk of developing RA or the severity of RA between postmenopausal women who were on hormone replacement therapy and those who took placebos. The study was published in the March issue of Arthritis Care & Research (http://www.interscience.wiley.com/journal/arthritiscare).

The WHI randomized controlled trials included over 27,000 postmenopausal women between the ages of 50 and 79 who took estrogen and progestin, estrogen alone or a placebo. Led by Brian Walitt of Washington Hospital Center in Washington, DC, the current study identified women who had RA based on whether they reported having it and were taking prescription medications to treat it. Self-reported information about whether women had RA was collected annually, and they were assessed for disease severity at the beginning of the study and after one year. Measures of self-reported joint pain/stiffness were also collected at that time and participants were asked to rate the severity of their symptoms.

The study is the only placebo-controlled trial to evaluate the effect of hormone replacement therapy on developing RA and the sixth study to evaluate the effects of hormone therapy on how women perceive disease severity. The results showed that there were 105 new cases and 63 existing cases of RA. There were no statistically significant differences on either new RA cases over an average of five to six years or on the severity of RA symptoms after one year. While earlier studies had suggested that hormones had a protective effect against developing RA, they were observational. The current study found no significant protective benefit from hormones in preventing RA.

Although the prevalence of RA in the study was about half of what is found in the general population, this may be due to the tendency of clinical trials to recruit healthier patients and the exclusion of participants taking prednisone, which is used to treat arthritis. Although the WHI methodology has many advantages over prior studies, the sample size for RA was much less than what would be required to observe the effect of hormone replacement therapy on developing RA. However, it is unlikely that larger studies will be carried out, due to the health risks of hormone replacement therapy. Also, the study relied on self-reported information, and even though it tried to minimize overreporting by including only women taking medications for RA, this approach is not as effective as performing chart reviews or physical exams.

The authors conclude that the design of the WHI provided a unique opportunity to examine the effects of PHT [postmenopausal hormone therapy] on RA. Despite the participation of 27,347 women, there was no statistically significant evidence of a difference in the hazard of RA incidence or a difference in RA symptom severity between the PHT and placebo groups.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
3. Hormone refractory prostate cancers more likely to spread to other organs
4. Newly discovered role of thyroid hormone during pregnancy
5. Stress hormone impacts memory, learning in diabetic rodents
6. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
7. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
8. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
9. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
10. FDA Warns Against Bio-Identical Hormone Therapy
11. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: